Sexton Riley LLP represented Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in its October 2021 collaboration agreement with Xencor, Inc. to develop and commercialize novel B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. https://investors.xencor.com/news-releases/news-release-details/xencor-enters-global-collaboration-and-license-agreement-janssen
top of page
bottom of page